Antibiotic Dosing in Patients on Intermittent Hemodialysis

Antibiotic Dosing in Patients on Intermittent Hemodialysis

The adequacy of the currently used dosing regimen of glycopeptides (vancomycin and teicoplanin) and beta-lactam antibiotics (amoxicillin-clavulanic acid, piperacillin-tazobactam, ceftazidim) in patients with end-stage kidney disease receiving intermittent hemodialysis is studied by evaluating pharmacokinetics-pharmacodynamics (PK-PD) target attainment. A population pharmacokinetic study is performed to assist the selection of the optimal individualized dose for patients undergoing intermittent dialysis, taking into consideration as many relevant variables as possible.

Inclusion Criteria:

• patients with end-stage kidney disease, requiring intermittent hemodialysis
• patient receiving antibiotic treatment for documented or presumed infection (vancomycin, teicoplanin, amoxicillin-clavulanic acid, piperacillin-tazobactam, ceftazidim)

Exclusion Criteria:

• pregnant woman
• absence of written informed consent from the patient
• known hypersensitivity or contra-indication to glycopeptides or beta-lactam antibiotics